Yearly Archives: 2009

­

Quark Pharmaceuticals Presents at Asia TIDES Conference

March 9th, 2009|

 Highlights First Systemic siRNA Administered in Humans and Quark’s Proprietary siRNA Structures

Fremont, CA – March 9, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development presented an overview of Quark’s novel pipeline of synthetic siRNA compounds […]

Quark Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

January 9th, 2009|

Kidney transplantation to be Quark’s second indication with clinical-stage, systemically administered siRNA product candidate

Fremont, CA – January 8, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)- based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically administered siRNA […]